BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 23558916)

  • 1. Rituximab faster infusion for patients with non-Hodgkin's lymphoma in the United States: implications for nursing practice.
    Dawson K
    J Infus Nurs; 2013; 36(3):172-8. PubMed ID: 23558916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab Faster Infusion for Patients With Non-Hodgkin's Lymphoma in the United States: Implications for Nursing Practice.
    Dawson K
    J Infus Nurs; 2015; 38 Suppl 6():S4-S10. PubMed ID: 26536411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab: a new monoclonal antibody therapy for non-Hodgkin's lymphoma.
    Kosits C; Callaghan M
    Oncol Nurs Forum; 2000; 27(1):51-9. PubMed ID: 10660923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid infusion rituximab changing practice for patient care.
    Al Zahrani A; Ibrahim N; Al Eid A
    J Oncol Pharm Pract; 2009 Sep; 15(3):183-6. PubMed ID: 19171551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Subcutaneous administration of MabThera for therapy of non-Hodgkin lymphomas frees patients and medical personnel].
    Pflege Z; 2013 Apr; 66(4):253. PubMed ID: 23634557
    [No Abstract]   [Full Text] [Related]  

  • 6. Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma.
    King KM; Younes A
    Expert Rev Anticancer Ther; 2001 Aug; 1(2):177-86. PubMed ID: 12113023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma.
    Boland A; Bagust A; Hockenhull J; Davis H; Chu P; Dickson R
    Health Technol Assess; 2009 Sep; 13 Suppl 2():41-8. PubMed ID: 19804688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peri-infusional adverse reactions to rituximab in patients with non-Hodgkin's lymphoma.
    Arredondo-Garza T; Majluf-Cruz A; Vela-Ojeda J; Mariscal-Ramírez I; Solis-Anaya L; Lopez-Gutiérrez JR; Guadarrama CH; Rico-Curiel E; Armenta-San Sebastián JA; Castañeda-Hernández G
    Arch Med Res; 2013 Oct; 44(7):549-54. PubMed ID: 24120421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma.
    Buckstein R; Imrie K; Spaner D; Potichnyj A; Robinson JB; Nanji S; Pennel N; Reis M; Pinkerton P; Dubé I; Hewitt K; Berinstein NL
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):115-22. PubMed ID: 10561026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab in the treatment of non-Hodgkin's lymphoma--a critical evaluation of randomized controlled trials.
    Griffin MM; Morley N
    Expert Opin Biol Ther; 2013 May; 13(5):803-11. PubMed ID: 23560506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab by subcutaneous route.
    Solal-Celigny P
    Expert Rev Hematol; 2015 Apr; 8(2):147-53. PubMed ID: 25749209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab (Rituxan/MabThera): the first decade (1993-2003).
    Grillo-López AJ
    Expert Rev Anticancer Ther; 2003 Dec; 3(6):767-79. PubMed ID: 14686699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom.
    Rule S; Collins GP; Samanta K
    J Med Econ; 2014 Jul; 17(7):459-68. PubMed ID: 24720836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Subcutaneous Rituximab is effective and safe].
    Häckel A
    Med Monatsschr Pharm; 2014 Jan; 37(1):39-40. PubMed ID: 24490439
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety and efficacy of non-initial rapid infusion of rituximab plus chemotherapy in Chinese patients with CD20+ non-Hodgkin's lymphoma.
    Zhao W; Gao Y; Bai B; Cai QC; Wang XX; Cai QQ; Huang HQ
    Expert Opin Drug Saf; 2015 Jan; 14(1):21-9. PubMed ID: 25412839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maintenance therapy for low-grade lymphomas: has the time come?
    Cartron G; Solal-Céligny P
    Curr Opin Oncol; 2007 Sep; 19(5):425-32. PubMed ID: 17762565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab: new indication. In aggressive non Hodgkin lymphoma: benefits must be confirmed.
    Prescrire Int; 2003 Aug; 12(66):125-6. PubMed ID: 12906019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.
    Grillo-López AJ; White CA; Varns C; Shen D; Wei A; McClure A; Dallaire BK
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):66-73. PubMed ID: 10561020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing the use of rituximab for treatment of B-cell non-Hodgkin's lymphoma: a benefit-risk update.
    Kunkel L; Wong A; Maneatis T; Nickas J; Brown T; Grillo-López A; Benyunes M; Grobman B; Dillman RO
    Semin Oncol; 2000 Dec; 27(6 Suppl 12):53-61. PubMed ID: 11226001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B reactivation in patient with non-Hodgkin's lymphoma receiving rituximab-based chemotherapy: need for education and attention.
    Yang JD; Girotra M; Vaid A; Duarte-Rojo A
    J Ark Med Soc; 2013 Nov; 110(6):110-2. PubMed ID: 24367885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.